Our results show that the prognostic impact of SETBP1 mutations is similar to that of ASXL1 mutations, which is one of the strongest independent negative prognostic factor [13, 20] in MDS and CMML patients (HR = 1.45, 95% CI (1.24–1.70)) [21]. This evidence concerns the gene SETBP1 and chronic myelomonocytic leukemia.